A nationwide Swedish prospective propensity score–matched cohort study suggests that lipophilic statins were associated with significantly reduced hepatocellular carcinoma (HCC) incidence and mortality. The study included 16 668 adults (8334 who initiated statin use [6554 lipophilic and 1780 hydrophilic] and 8334 nonusers) among 63 279 eligible adults with chronic hepatitis B or C. Compared with matched nonusers, 10-year HCC risk was significantly lower among lipophilic statin users (8.1% vs. 3.3%; adjusted subdistribution hazard ratio [aHR], 0.56) but not hydrophilic statin users (8.0% vs. 6.8%; aHR, 0.95). The inverse association between lipophilic statins and HCC risk seemed to be dose-dependent. Compared with nonusers, 10-year HCC risk was lowest with 600 or more lipophilic statin cumulative defined daily doses (8.4% vs. 2.5%; aHR, 0.41), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%) and hydrophilic (16.0% vs. 11.5%) statin users. The findings are consistent with preclinical studies. Source: https://annals.org/
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.